"Navigating the Modern News Zoo so you don't have to."
Wednesday, April 30, 2025
Adjuvant PD-1 blockade for mismatch repair-deficient solid cancers directed by ctDNA status delivers clinical benefit
Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who had detectable circulating tumor DNA (ctDNA) after resection, according to preliminary results from a phase II trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.
Psycho Runs Over Cop during DUI Traffic Stop
- Backblaze responds to claims of “sham accounting,” customer backups at risk - Scharon Harding
- First 'smart,' wearable, pediatric soft exoskeleton provides mobility for children with motor difficulties
- With Diego Garcia Military Base in the Balance, ‘The Chagos Farce’ is No Laughing Matter - Deroy Murdock
- Researchers secretly experimented on Reddit users with AI-generated comments - Karissa Bell
- Colon Cancer Is on the Rise in Young People—Is a Bacterial Toxin to Blame? - Jamie Ducharme
- Your Favorite Sci-Fi TV Show Will Never Be As Successful As NCIS - Jonathan Klotz
Finally, a Slim and Solid Samsung Midrange Phone! ft. Galaxy M56 5G
- FDA Suspends Key Milk Safety Program—What This Means For You - Jenna Anderson
- Gentner Drummond’s Bad Choices for Oklahoma - Dan McLaughlin
- How To Manage Dry Eyes With Contact Lenses - Suchandrima Bhowmik
- Star Trek: Voyager's Best Special Effect Was Almost A Disappointment - Chris Snellgrove
- EA and Respawn lay off more staff, cancel incubation projects - Rachel Kaser
- How Volcanoes Shaped Buffy The Vampire Slayer Wild Episode - Chris Snellgrove
